Patents Assigned to PHARMECOSSE LIMITED
  • Patent number: 9308240
    Abstract: Insulin or a peroxisome proliferator-activated receptor (PPAR) agonist provides reliable and effective prevention of scarring in human skin, or at least a reduction in the severity of scarring. The application of insulin or the PPAR agonist to wounds topically or by local injection is particularly advantageous since it simultaneously reduces/prevents scarring while enhancing re-epithelialization of the wound and thus provides a dual action wound healing treatment. The present invention accordingly provides a highly effective prophylactic treatment for any individual suffering tissue trauma to reduce and/or prevent normal and/or pathological scarring.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: April 12, 2016
    Assignee: Pharmecosse Limited
    Inventors: Claire Linge, Ian Paul Mackie
  • Publication number: 20140155322
    Abstract: Insulin or a peroxisome proliferator-activated receptor (PPAR) agonist provides reliable and effective prevention of scarring in human skin, or at least a reduction in the severity of scarring. The application of insulin or the PPAR agonist to wounds topically or by local injection is particularly advantageous since it simultaneously reduces/prevents scarring whilst enhancing re-epithelialisation of the wound and thus provides a dual action wound healing treatment. The present invention accordingly provides a highly effective prophylactic treatment for any individual suffering tissue trauma to reduce and/or prevent normal and/or pathological scarring.
    Type: Application
    Filed: September 12, 2013
    Publication date: June 5, 2014
    Applicant: PHARMECOSSE LIMITED
    Inventors: Claire Linge, Ian Paul Mackie